NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)<
06 Oct 2021

Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)

This venture debt operation is supported by the European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.
Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival<
30 Sep 2021

Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

This study confirms our previous findings and the clinical utility of MAF Test® as a unique tool for precision medicine in early breast cancer.

Aura Biosciences Expands Executive Leadership Team and Board of Directors<
29 Sep 2021

Aura Biosciences Expands Executive Leadership Team and Board of Directors

Appointment of Chris Primiano, J.D., as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.
CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up<
21 Sep 2021

CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up

Two seasoned industry experts are joining the company: Paul Cornelison (USA) as Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs, and Michael Webb (Australia) as Vice President, Manufacturing.
AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.<
15 Sep 2021

AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

Lars’ experience as a CFO at companies as they move toward commercialization will contribute greatly to AM-Pharma’s strengths and we are excited to welcome him.
Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis<
14 Sep 2021

Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications.
Ysios Capital achieves Certification under the Diversity VC Standard<
09 Sep 2021

Ysios Capital achieves Certification under the Diversity VC Standard

Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard.
AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan<
08 Sep 2021

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

Overall deal value is up to EUR 245 million.
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease<
13 Aug 2021

VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies<
13 Jul 2021

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies

LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка